Table 2.
Characteristics of the IGRA-tested patients, overall and stratified by IGRA score.
| Characteristics | IGRA Results | p Value | ||||
|---|---|---|---|---|---|---|
| Total | Negative | Positive | Indeterminate | |||
| 260 | 228 (87.7) | 21 (8.1) | 11 (4.2) | |||
| n (%) | n (%) | n (%) | n (%) | |||
| Sex | Female | 116 (44.6) | 105 (46.1) | 7 (33.3) | 4 (36.4) | 0.496 |
| Male | 144 (55.4) | 123 (53.9) | 14 (66.7) | 7 (63.3) | ||
| Foreign born | No | 236 (90.8) | 206 (90.4) | 20 (95.2) | 10 (90.9) | 0.883 |
| Yes | 24 (9.2) | 22 (9.6) | 1 (4.8) | 1 (9.1) | ||
| Age, median (IQR) | 53 (44–60) | 52 (42–59) | 60 (58–64) | 57 (49–59) | <0.001 | |
| Year of transplant | 2015 | 55 (21.2) | 48 (21.0) | 5 (23.8) | 2 (18.2) | 0.998 |
| 2016 | 55 (21.2) | 48 (21.0) | 5 (23.8) | 2 (18.2) | ||
| 2017 | 55 (21.2) | 48 (21.0) | 5 (23.8) | 2 (18.2) | ||
| 2018 | 49 (18.8) | 42 (18.5) | 5 (23.8) | 2 (18.2) | ||
| 2019 | 46 (17.6) | 42 (18.5) | 1 (4.8) | 3 (27.2) | ||
| Type of transplant | Autologous | 51 (19.6) | 44 (19.3) | 7 (33.3) | 0 (0) | 0.074 |
| Allogenic | 209 (80.4) | 184 (80.7) | 14 (66.7) | 11 (100) | ||
| Type of allogenic transplant | HLA identical sibling | 54 (25.8) | 43 (23.4) | 5 (35.7) | 6 (54.5) | 0.301 |
| HLA matched other relative | 1 (0.5) | 1 (0.6) | 0 (0) | 0 (0) | ||
| HLA mismatched relative | 30 (14.4) | 27 (14.7) | 1 (7.1) | 2 (18.2) | ||
| Syngeneic | 2 (0.9) | 2 (1.0) | 0 (0) | 0 (0) | ||
| Unrelated | 122 (58.4) | 111 (60.3) | 8 (57.2) | 3 (27.3) | ||
|
Source
of transplant |
Umbilical cord blood | 2 (0.8) | 2 (0.9) | 0 (0) | 0 (0) | 0.507 |
| Bone marrow | 68 (26.1) | 59 (25.9) | 4 (19.1) | 5 (45.5) | ||
| Bone marrow+PBSC | 1 (0.4) | 1 (0.4) | 0 (0) | 0 (0) | ||
| PBSC | 189 (72.7) | 166 (72.8) | 17 (80.9) | 6 (54.5) | ||
| Conditioning regimen | TBF | 205 (78.8) | 180 (78.9) | 14 (66.7) | 11 (100) | 0.139 |
| Melphalan | 25 (9.6) | 19 (8.3) | 6 (28.6) | 0 (0) | ||
| FEAM | 21 (8.1) | 20 (8.8) | 1 (4.7) | 0 (0) | ||
| Other regimen | 9 (3.5) | 9 (4.0) | 0 (0) | 0 (0) | ||
| Laboratory results | White Blood cells/mmc, median (IQR) | 3520 (2690–4850) |
3445 (2690–4840) |
4500 (3590–4920) |
3000 (1040–4250) |
0.114 |
| Neutrophils/mmc, median (IQR) |
1905 (1185–2820) |
1895 (1185–2820) |
2300 (1220–2890) |
1760 (550–2700) |
0.821 | |
| Lymphocytes/mmc, median (IQR) | 1010 (690–1470) |
1010 (690–1460) |
1190 (830–2060) |
600 (280–1010) |
0.009 | |
| Monocytes/mmc, median (IQR) |
360 (250–490) |
360 (240–470) |
450 (350–530) |
450 (210–530) |
0.044 | |
| Diagnosis | SAA | 1 (0.4) | 1 (0.4) | 0 (0) | 0 (0) | |
| BMF | 1 (0.4) | 1 (0.4) | 0 (0) | 0 (0) | ||
| CLL | 3 (1.1) | 2 (0.9) | 1 (4.8) | 0 (0) | ||
| LA Second | 7 (2.7) | 6 (2.6) | 1 (4.8) | 0 (0) | ||
| HL | 11 (4.2) | 11 (4.8) | 0 (0) | 0 (0) | ||
| ALL | 36 (13.9) | 32 (14.0) | 3 (14.2) | 1 (9.1) | ||
| AML | 94 (36.1) | 85 (37.3) | 3 (14.2) | 6 (54.5) | ||
| CML | 3 (1.1) | 2 (0.9) | 1 (4.8) | 0 (0) | ||
| NHL | 38 (14.6) | 34 (14.9) | 2 (9.5) | 2 (18.2) | ||
| MDS | 22 (8.5) | 17 (7.5) | 4 (19.1) | 1 (9.1) | ||
| MM | 36 (13.9) | 30 (13.2) | 6 (28.6) | 0 (0) | ||
| MPS | 8 (3.1) | 7 (3.1) | 0 (0) | 1 (9.1) | ||
IGRA: Interferon gamma release assay; IQR: interquartile range; PBSC: peripheral blood stem cells; TBF: thiothepa, busulfan, fludarabine; FEAM: fotemustine, etoposide, cytarabine and melphalan; SAA: severe aplastic anemia; BMF: bone marrow failure; CLL chronic lymphatic leukemia; HL: Hodgkin’s lymphoma; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; NHL: non-Hodgkin’s lymphoma; MDS: myelodysplastic syndrome; MM: multiple myeloma; MPS: myeloproliferative syndromes.